Some PH patients with interstitial lung disease may benefit from oral PAH drugs

Medications for pulmonary arterial hypertension (PAH) are not approved for use in patients with pulmonary hypertension due to interstitial lung disease (PH-ILD, part of Group 3 PH). This study looked at whether PH-ILD patients benefited from PAH medications. They found no benefit to patients' functional class, pulmonary function tests, or six-minute walk distances, but they did see improvements in NT-proBNP (a measure of heart function) and blood flow. This study was too small to do so but, in future, precision medicine may be able to identify PH-ILD patients who may benefit from PAH drugs.

Read the Journal of Clinical Medicine Research article